Novartis buys Kate Therapeutics for up to $1.1B to boost gene therapy for neuromuscular diseases.

Novartis has acquired Kate Therapeutics for up to $1.1 billion to expand its gene therapy offerings for neuromuscular diseases. Kate Therapeutics specializes in gene therapies targeting conditions like Duchenne muscular dystrophy. The deal includes upfront payments and potential future milestones, aiming to enhance Novartis' capabilities in treating complex neuromuscular diseases.

November 21, 2024
4 Articles

Further Reading